REG - Assura plc - Scrip Dividend Declaration

AssuraAnnouncement

07/10/2024 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20241007:nRSG0607Ha&default-theme=true

RNS Number : 0607H  Assura PLC  07 October 2024

7 October 2024

Assura plc

Scrip Dividend Declaration

Assura plc ("Assura" or "the Company"), the diversified healthcare REIT, today
announces that, pursuant to its Scrip Dividend Scheme and in response to the
scrip dividend alternative for the quarterly interim dividend payable on 9
October 2024 (the "Scrip Dividend Alternative"), elections were received in
respect of 22.1 per cent. of the Company's ordinary shares in issue as at the
record date of 6 September 2024.

Electing shareholders will receive ordinary shares in the Company ("Shares")
in lieu of cash in respect of this dividend and, accordingly 13,657,643 Shares
(the "New Shares") will be issued by the Company to such shareholders.

Application has therefore been made for the admission of the New Shares to the
Official List of the Financial Conduct Authority and to trading on the London
Stock Exchange's market for listed securities ("Admission"). The New Shares
will rank pari passu with the Company's existing ordinary shares and Admission
is expected to occur at 8.00am on 9 October 2024.

Following the allotment of the New Shares, it is expected that the total
number of shares in issue will be 3,250,608,887 (none of which will be held in
treasury) and that, accordingly, the total number of voting rights of the
Company will be 3,250,608,887.

Copies of the documents relating to the Scrip Dividend Alternative are
available for inspection through the National Storage Mechanism
(https://data.fca.org.uk/#/nsm/nationalstoragemechanism
(https://data.fca.org.uk/#/nsm/nationalstoragemechanism) ).

This interim dividend is 100% Property Income Distribution ("PID"). Forms to
register for gross PIDs (on future interim dividends) are available on the
Company's website. Please click here for PID Forms
(http://assuraplc.com/investor-relations/shareholder-information/reit-dividends-and-uk-tax)
.

- ENDS -

For more information, please contact:

 

 Assura plc                                   Tel: 0161 515 2043
 David Purcell, Investor Relations Director   Email: Investor@assura.co.uk
 FGS Global                                   Tel: 0207 251 3801
 Gordon Simpson                               Email: Assura@fgsglobal.com

Notes to Editors

Assura plc is the UK's leading diversified healthcare REIT. Assura enables
better health outcomes through its portfolio of more than 600 healthcare
buildings, from which over six million patients are served.

A UK REIT based in Altrincham, Assura is a constituent of the FTSE 250 and the
EPRA* indices. As at 31 March 2024, Assura's portfolio was valued at £2.7
billion and has a strong track record of growing financial returns and
dividends for shareholders.

At Assura, we BUILD for health, having developed over 100 new healthcare
buildings in our history, and at the heart of our strategy sits The Bigger
Picture; Healthy Environment (E), Healthy Communities (S), Healthy Business
(G).

Further information is available at www.assuraplc.com
(http://www.assuraplc.com)

Assura plc LEI code: 21380026T19N2Y52XF72

*EPRA is a registered trademark of the European Public Real Estate
Association.

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  DIVBUBDGXUGDGSS